121 related articles for article (PubMed ID: 33262410)
1. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Zhang Z; Lian X; Xie W; Quan J; Liao M; Wu Y; Yang ZZ; Wang G
Sci Rep; 2020 Dec; 10(1):20924. PubMed ID: 33262410
[TBL] [Abstract][Full Text] [Related]
2. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Nilsson MB; Sun H; Diao L; Tong P; Liu D; Li L; Fan Y; Poteete A; Lim SO; Howells K; Haddad V; Gomez D; Tran H; Pena GA; Sequist LV; Yang JC; Wang J; Kim ES; Herbst R; Lee JJ; Hong WK; Wistuba I; Hung MC; Sood AK; Heymach JV
Sci Transl Med; 2017 Nov; 9(415):. PubMed ID: 29118262
[TBL] [Abstract][Full Text] [Related]
3. EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Fung C; Chen X; Grandis JR; Duvvuri U
Cancer Biol Ther; 2012 Dec; 13(14):1417-24. PubMed ID: 22954701
[TBL] [Abstract][Full Text] [Related]
4. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
Xu X; Liu Y; Gong Q; Ma L; Wei W; Zhao L; Luo Z
Cancer Chemother Pharmacol; 2024 Apr; ():. PubMed ID: 38609654
[TBL] [Abstract][Full Text] [Related]
5. Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression.
Sun Z; Li L; Zhai B; Hu M; Huang L; Huang S; Ye L; Kong X; Xu J; Bai J; Yan J; Zhou Q; Hu Z; Zhang Y; Jiang Y; Zhang Y; Qiao Z; Zou Y; Xu Y; Zhu Q
J Med Chem; 2024 Mar; 67(6):4916-4935. PubMed ID: 38477575
[TBL] [Abstract][Full Text] [Related]
6. USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy.
Young MJ; Wang SA; Chen YC; Liu CY; Hsu KC; Tang SW; Tseng YL; Wang YC; Lin SM; Hung JJ
Cell Death Differ; 2024 May; 31(5):574-591. PubMed ID: 38491202
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
[TBL] [Abstract][Full Text] [Related]
10. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA
J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873
[TBL] [Abstract][Full Text] [Related]
11. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
Front Immunol; 2020; 11():527750. PubMed ID: 33324391
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.
Gavralidis A; Gainor JF
Cancer J; 2020; 26(6):517-524. PubMed ID: 33298723
[TBL] [Abstract][Full Text] [Related]
13. SIRT1 - a new mammalian substrate of nuclear autophagy.
Wang L; Xu C; Johansen T; Berger SL; Dou Z
Autophagy; 2021 Feb; 17(2):593-595. PubMed ID: 33292048
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
Garon EB; Kim JS; Govindan R
Lung Cancer; 2021 Jan; 151():25-29. PubMed ID: 33285468
[TBL] [Abstract][Full Text] [Related]
15. Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
Jin J; Robeson H; Fagan P; Orloff MS
PLoS One; 2020; 15(12):e0243509. PubMed ID: 33284833
[TBL] [Abstract][Full Text] [Related]
16. Changing paradigm in advanced and metastatic non-small cell lung cancer.
Uprety D; Parikh K; Sawkar A; Dimou A; Leventakos K
J Thorac Dis; 2020 Nov; 12(11):6992-7001. PubMed ID: 33282404
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting.
Houssaini MS; Damou M; Ismaili N
Cancer Treat Res Commun; 2020; 25():100239. PubMed ID: 33271494
[TBL] [Abstract][Full Text] [Related]
18. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
Buder A; Hochmair MJ; Filipits M
Target Oncol; 2021 Jan; 16(1):77-84. PubMed ID: 33270169
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer.
Wohlhieter CA; Richards AL; Uddin F; Hulton CH; Quintanal-Villalonga À; Martin A; de Stanchina E; Bhanot U; Asher M; Shah NS; Hayatt O; Buonocore DJ; Rekhtman N; Shen R; Arbour KC; Donoghue M; Poirier JT; Sen T; Rudin CM
Cell Rep; 2020 Dec; 33(9):108444. PubMed ID: 33264619
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein 9 (BMP9) directly induces Notch effector molecule Hes1 through the SMAD signaling pathway in osteoblasts.
Seong CH; Chiba N; Kusuyama J; Subhan Amir M; Eiraku N; Yamashita S; Ohnishi T; Nakamura N; Matsuguchi T
FEBS Lett; 2021 Feb; 595(3):389-403. PubMed ID: 33264418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
